Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Persistent Asthma Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02513160
• Other study ID #: BDB-AS-30039
• Secondary ID: 2015-002510-80
• Status: Completed
• Phase: Phase 3
• Start date: September 30, 2015
• Est. completion date: March 31, 2016

Study information

• Verified date: November 2021
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy of beclomethasone dipropionate administered via BAI at a dose strength of 40 or 80 mcg per oral inhalation (320 or 640 mcg/day, respectively) compared with placebo treatment in patients with persistent asthma as assessed by the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator) forced expiratory volume in 1 second (FEV1) area under the effect curve from time 0 to 6 weeks (AUEC[0-6wk]).

Description:

Run-In Period (Days -14 to Day -1): Participants were provided with single-blind placebo breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) device for twice-daily use after appropriate training and demonstration of the proper technique. Participants discontinued their current asthma therapy for the duration of the study. Treatment Period (Day 0 to Week 6): Participants were randomly assigned to treatment and device type through a qualified randomization service provider (ie, IRT). The interactive response technology (IRT) system stratified patients based on treatment at the time of screening visit, either inhaled corticosteroid (ICS) or non-corticosteroid (NCS). During the study, blinded persons were blinded to treatment (active or placebo) assigned but not device (BAI or MDI) assignment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 713
• Est. completion date: March 31, 2016
• Est. primary completion date: March 31, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• The patient has a diagnosis of asthma as defined by the NIH. The asthma diagnosis
• has been present for a minimum of 3 months and has been stable (defined as no exacerbations and no changes in medication) for at least 30 days.
• The patient has been maintained on stable doses of :
• non-corticosteroid therapy
• inhaled corticosteroid therapy
• Written informed consent/assent is obtained. For adult patients (18 years of age and older, or as applicable per local regulations), the written informed consent form (ICF) must be signed and dated by the patient before conducting any study-related procedure. For minor patients (ages 12 to 17 years, or as applicable per local regulations), the written ICF must be signed and dated by the parent/legal guardian and the written informed assent form must be signed and dated by the patient before conducting any study-related procedure.
• The patient is a male or female 12 years of age or older as of the visit when informed consent/assent is signed (screening or prescreening visit, as applicable). (Note: Age requirements are as specified or allowed by local regulations.)
• The patient is able to perform acceptable and repeatable spirometry
• The patient is able to use an electronic diary after training.
• The patient is able to use devices properly
• If female, patient is currently not pregnant, not breast feeding, nor attempting to become pregnant (for 30 days before the screening visit (SV) and throughout the duration of the study and for 30 days after patient's last study visit) or, is of childbearing potential and not sexually active, has a negative urine pregnancy test, and is willing to commit to using a consistent and acceptable method of birth control
• If male, the patient is willing to commit to an acceptable method of birth control for the duration of the study, is surgically sterile or exclusively has same-sex partner(s).
• The patient does not have any concomitant conditions or treatments that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study as judged by the investigator.
• The patient/parent/legal guardian is capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements (eg, dose schedules, visit schedules, procedures, and record keeping).
• The patient, as judged by the investigator, is able to discontinue all asthma medications at the SV.
• other criteria apply, please contact the investigator for more information Exclusion Criteria
• Life-threatening asthma, defined as a history of asthma episode(s) requiring intubation and/or associated with hypercapnea, respiratory arrest or hypoxic seizures, asthma-related syncopal episode(s), or hospitalizations within the past year.
• The patient received systemic corticosteroids within 30 days before the SV (for asthma exacerbation or for other indications).
• The patient has participated in any investigational drug study as a randomized patient within the 30 days (starting at the final visit of that study) preceding SV (or prescreening visit, as applicable), or plans to participate in another investigational drug study at any time during this study.
• The patient has previously participated in a beclomethasone dipropionate breath-actuated inhaler (device) (BAI) study as a randomized patient.
• The patient has a known hypersensitivity to any corticosteroid or any of the excipients in the study drug or rescue medication formulation.
• The patient has been treated with any known strong cytochrome inhibitors during the study.
• The patient has been treated with any of the prohibited medications during the prescribed (per protocol) withdrawal periods before the SV.
• The patient currently smokes or has a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient may not have used tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco).
• The patient has a suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that has not resolved at least 2 weeks before the SV.
• The patient has a history of alcohol or drug abuse within 2 years preceding SV.
• The patient has had an asthma exacerbation requiring oral corticosteroids within 1 month before the SV, or has had any hospitalization for asthma within 3 months before SV.
• The patient has initiated immunotherapy (administered by any route) less than 90 days before the SV or had a dose escalation of immunotherapy less than 30 days before the SV.
• The patient is unable to tolerate or unwilling to comply with the required washout periods and withholding of all applicable medications.
• The patient has untreated oral candidiasis at SV. Patients with clinical visual evidence of oral candidiasis and who agree to receive treatment and comply with appropriate medical monitoring may enter the study.
• The patient is either an employee or an immediate relative of an employee of the clinical investigational center.
• A member of the patient's household is participating in the study at the same time. (However, after the enrolled patient completes or discontinues participation in the study, another patient from the same household may be screened).
• The patient has a disease/condition that, in the medical judgment of the investigator, would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.
• other criteria apply, please contact the investigator for more information

Related Conditions & MeSH terms

• Asthma
• Persistent Asthma

Intervention

Drug:
• Beclomethasone Dipropionate 640
Beclomethasone Dipropionate 640 mcg BAI
• Placebo
Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices. The placebo devices were identical to the devices used to deliver active drug.
• Beclomethasone dipropionate via 320 mcg BAI
Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
• albuterol/salbutamol
Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
• Beclomethasone dipropionate via 320 mcg MDI
Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).

Locations

Country	Name	City	State
United States	Teva Investigational Site 13400	Austin	Texas
United States	Teva Investigational Site 13404	Aventura	Florida
United States	Teva Investigational Site 13410	Baltimore	Maryland
United States	Teva Investigational Site 13384	Bellevue	Nebraska
United States	Teva Investigational Site 13422	Bethesda	Maryland
United States	Teva Investigational Site 13452	Boerne	Texas
United States	Teva Investigational Site 13392	Brick	New Jersey
United States	Teva Investigational Site 13395	Canton	Ohio
United States	Teva Investigational Site 13397	Centennial	Colorado
United States	Teva Investigational Site 13396	Cincinnati	Ohio
United States	Teva Investigational Site 13433	Columbia	Missouri
United States	Teva Investigational Site 13407	Dallas	Texas
United States	Teva Investigational Site 13424	Dallas	Texas
United States	Teva Investigational Site 13454	Denver	Colorado
United States	Teva Investigational Site 13389	Downey	California
United States	Teva Investigational Site 13449	East Providence	Rhode Island
United States	Teva Investigational Site 13409	El Paso	Texas
United States	Teva Investigational Site 13453	Eugene	Oregon
United States	Teva Investigational Site 13428	Greenfield	Wisconsin
United States	Teva Investigational Site 13458	Hialeah	Florida
United States	Teva Investigational Site 13441	Hickory	North Carolina
United States	Teva Investigational Site 13451	Houston	Texas
United States	Teva Investigational Site 13421	Huntington Beach	California
United States	Teva Investigational Site 13434	Huntington Beach	California
United States	Teva Investigational Site 13390	Knoxville	Tennessee
United States	Teva Investigational Site 13442	Knoxville	Tennessee
United States	Teva Investigational Site 13439	Lake Oswego	Oregon
United States	Teva Investigational Site 13408	Lenexa	Kansas
United States	Teva Investigational Site 13427	Los Angeles	California
United States	Teva Investigational Site 13402	Medford	Oregon
United States	Teva Investigational Site 13416	Miami	Florida
United States	Teva Investigational Site 13440	Miami	Florida
United States	Teva Investigational Site 13455	Miami	Florida
United States	Teva Investigational Site 13386	Mission Viejo	California
United States	Teva Investigational Site 13399	New Braunfels	Texas
United States	Teva Investigational Site 13450	Normal	Illinois
United States	Teva Investigational Site 13413	North Charleston	South Carolina
United States	Teva Investigational Site 13411	North Dartmouth	Massachusetts
United States	Teva Investigational Site 13426	Ocean City	New Jersey
United States	Teva Investigational Site 13387	Oklahoma City	Oklahoma
United States	Teva Investigational Site 13394	Orange	California
United States	Teva Investigational Site 13431	Ormond Beach	Florida
United States	Teva Investigational Site 13415	Peoria	Arizona
United States	Teva Investigational Site 13391	Pittsburgh	Pennsylvania
United States	Teva Investigational Site 13398	Plymouth	Minnesota
United States	Teva Investigational Site 13429	Plymouth	Minnesota
United States	Teva Investigational Site 13412	Portland	Oregon
United States	Teva Investigational Site 13403	Raleigh	North Carolina
United States	Teva Investigational Site 13385	Richmond	Virginia
United States	Teva Investigational Site 13447	Richmond	Virginia
United States	Teva Investigational Site 13448	River Forest	Illinois
United States	Teva Investigational Site 13417	Riverside	California
United States	Teva Investigational Site 13388	Rochester	New York
United States	Teva Investigational Site 13432	Rolla	Missouri
United States	Teva Investigational Site 13445	Rolling Hills Estates	California
United States	Teva Investigational Site 13414	Saint Louis	Missouri
United States	Teva Investigational Site 13430	Saint Louis	Missouri
United States	Teva Investigational Site 13393	San Antonio	Texas
United States	Teva Investigational Site 13444	San Antonio	Texas
United States	Teva Investigational Site 13446	San Antonio	Texas
United States	Teva Investigational Site 13457	San Antonio	Texas
United States	Teva Investigational Site 13459	San Antonio	Texas
United States	Teva Investigational Site 13420	San Diego	California
United States	Teva Investigational Site 13443	San Diego	California
United States	Teva Investigational Site 13438	San Jose	California
United States	Teva Investigational Site 13437	Sarasota	Florida
United States	Teva Investigational Site 13419	Skillman	New Jersey
United States	Teva Investigational Site 13401	South Burlington	Vermont
United States	Teva Investigational Site 13436	Sylvania	Ohio
United States	Teva Investigational Site 13425	Tallahassee	Florida
United States	Teva Investigational Site 13423	Toledo	Ohio
United States	Teva Investigational Site 13383	Waco	Texas
United States	Teva Investigational Site 13456	Warwick	Rhode Island
United States	Teva Investigational Site 13435	Wheaton	Maryland
United States	Teva Investigational Site 13405	Wilmington	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Teva Branded Pharmaceutical Products R&D, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 6 Weeks (AUEC(0-6wk))	The primary efficacy variable was the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator) FEV1 AUEC(0-6wk). Pulmonary function measurements such as FEV1 were obtained electronically by spirometry at the randomization visit, each treatment visit (Weeks 2, 4 and 6) and any unscheduled visit (such as the early termination visit). The highest FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 8 attempts) was used. The least-square (LS) means, difference of LS means and its 95% confidence interval (CI), and p-value represent the results obtained from the analysis of covariance with covariate adjustment for baseline, sex, age, current asthma therapy, and treatment.	Baseline (Day 0 of Treatment Period), weeks 2, 4, 6
Secondary	Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Rate Over the 6-Week Treatment Period	Change from baseline in the weekly average of daily trough morning (pre-dose and pre-rescue bronchodilator) PEF by handheld spirometer over the 6-week treatment period. PEF were determined twice daily, in the morning and in the evening, before administration of study drug or rescue medications. A handheld spirometer was provided to patients and used to determine the morning and evening PEF throughout the study. The spirometer was programmed to record the highest PEF obtained from 3 valid attempts. Baseline was defined as the average of recorded trough morning PEF assessments over the 7 days prior to the first dose of double-blind study treatment, including the morning assessment at the randomization visit. The LS means, difference of LS means and its 95% confidence interval, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week, and treatment by week interaction.	Timeframes: Baseline (Day -7 to Day 0 which is part of the Run-in Period); Treatment Period from Day 0 up to 6 weeks
Secondary	Change From Baseline in Weekly Average of Daily Trough Morning Forced Expiratory Volume in One Minute (FEV1) Rate Over the 6-Week Treatment Period	Change from baseline in the weekly average of daily trough morning (pre-dose and pre-rescue bronchodilator) FEV1 by handheld spirometer over the 6-week treatment period. FEV1 were determined twice daily, in the morning and in the evening, before administration of study drug or rescue medications. A handheld spirometer was provided to patients and used to determine the morning and evening FEV1 throughout the study. The spirometer was programmed to record the highest FEV1 obtained from 3 valid attempts. Baseline was defined as the average of recorded trough morning FEV1 assessments over the 7 days prior to the first dose of double-blind study treatment, including the morning assessment at the randomization visit. The LS means, difference of LS means and its 95% confidence interval, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week, and treatment by week interaction.	Baseline (Day -7 to Day 0 which is part of the Run-in Period); Treatment Period from Day 0 up to 6 weeks
Secondary	Change From Baseline in Weekly Average of Total Daily (24-Hour) Rescue Medication Use Over the 6-Week Treatment Period	Change from baseline in the weekly average of total daily (24-hour) use of albuterol/salbutamol inhalation aerosol over weeks 1 through 6. Patients recorded the number of inhalations (puffs used) of rescue medication (albuterol/salbutamol HFA MDI [90 mcg ex-actuator] or equivalent) each morning and evening in the diary. The average number of daily inhalations over the 7 days before the randomization visit was the baseline value and was compared with the rescue medication use during the 6-week treatment period.	Baseline (Day -7 to Day 0 which is part of the Run-in Period); Treatment Period from Day 0 up to 6 weeks
Secondary	Change From Baseline in Weekly Average of Total Daily Asthma Symptom Score Over the 6-Week Treatment Period	Asthma symptom scores were recorded in the patient's diary each morning and evening before determining FEV1 and PEF and before administration of study or rescue medications. The Daytime Symptom Score was recorded in the evening on a scale of 0 (No symptoms during the day) to 5 (Symptoms so severe that I could not go to work or perform normal daily activities) plus the Nighttime Symptom Score in the morning on a scale of 0 (No symptoms during the night) to 4 (Symptoms so severe that I did not sleep at all) for a total score range of 0-9. Baseline was defined as the average of recorded daily asthma symptom scores (average of daytime and nighttime score) over the 7 days prior to the first dose of double-blind study treatment, including the morning assessment at the randomization visit. The LS means, difference of LS means and its 95% CI, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asth	Baseline (Day -7 to Day 0 which is part of the Run-in Period); Treatment Period from Day 0 up to 6 weeks
Secondary	Count of Participants Withdrawn From Study Drug Treatment Due to Meeting Stopping Criteria for Worsening Asthma	Number of participants who were withdrawn from study drug due to worsening asthma. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture was consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety. An example of an alert criteria is: Morning FEV1 by handheld spirometer as measured at home falls below the FEV1 stability limit (FEV1 <80%) as calculated at the screening visit for the Run-in Period and at the randomization visit (Day 0) for the Treatment Period on 4 or more days out of any 7-day period.	Day 0 to Week 6
Secondary	Participants With Treatment-Emergent Adverse Events (TEAE)	An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly/birth defect, or an important medical event that may not result in death, be life-threatening, or require hospitalization, but may jeopardize the patient and may require medical intervention to prevent one of the outcomes listed in this definition.	Day 0 to Week 6